Skip to content
  • Debatforum
  • Seneste
  • Populære
  • Bruger
Temaer
  • Light
  • Dark

Kollaps
FORSIDEN
Log ind Opret konto

Genmab — Oktober 2020

Planlagt Fastgjort Låst Flyttet Genmab
767 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • BulderB Offline
    BulderB Offline
    Bulder
    wrote on sidst redigeret af
    #645

    Lad os antage at det svarer til 4 mia $. 10% heraf er 400 mio $.

    1 Reply Last reply
    0
    • E Offline
      E Offline
      E_L
      wrote on sidst redigeret af
      #646

      PRAC agenda: 5.3.4. Carfilzomib - KYPROLIS (CAP) - EMEA/H/C/003790/II/0045, Orphan
      Applicant: Amgen Europe B.V.

      Scope: Extension of existing indication to include combination of Kyprolis (carfilzomib) with
      daratumumab and dexamethasone. As a consequence, sections 4.1, 4.2, 4.8 and 5.1 of the
      SmPC are updated. The package leaflet is updated in accordance
      Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

      1 Reply Last reply
      0
      • BulderB Offline
        BulderB Offline
        Bulder
        wrote on sidst redigeret af
        #647

        Professor ærgrer sig over Medicinrådets afvisning af Dar MPV https://haematologisktidsskrift.dk/2-uncategorised/768-professor-aergrer-sig-over-medicinradets-afvisning-af-dar-mpv.html

        1 Reply Last reply
        0
        • Helge_LarsenPI-redaktørH Offline
          Helge_LarsenPI-redaktørH Offline
          Helge_LarsenPI-redaktør
          wrote on sidst redigeret af
          #648

          Ses vi kl. 17? https://event.webinarjam.com/register/8/rp8nvfw

          1 Reply Last reply
          0
          • BulderB Offline
            BulderB Offline
            Bulder
            wrote on sidst redigeret af
            #649

            Belamaf på dansk https://haematologisktidsskrift.dk/sygdomme/myeloma/761-fda-haster-myelomatose-middel-ud-pa-markedet.html

            1 Reply Last reply
            0
            • K Offline
              K Offline
              Klarussen
              wrote on sidst redigeret af
              #650

              Køber i 2050,- vi er der snart 😉

              1 Reply Last reply
              0
              • E Offline
                E Offline
                E_L
                wrote on sidst redigeret af
                #651

                New trial - A Study of Amivantamab Subcutaneous (SC) Administration for the Treatment of Advanced Solid Malignancies https://www.clinicaltrials.gov/ct2/show/NCT04606381?term=rHuPH20&lupd_s=10%2F27%2F2020&draw=2&rank=1

                1 Reply Last reply
                0
                • E Offline
                  E Offline
                  E_L
                  wrote on sidst redigeret af
                  #652

                  exactly 100 dkk high -> low . #UselessFacts

                  1 Reply Last reply
                  0
                  • G Offline
                    G Offline
                    GeorgeBest
                    wrote on sidst redigeret af
                    #653

                    https://twitter.com/wattwurm73/status/1321464818776375296?s=21 HALOs teknologi anvendes også til Amivantamab sc!

                    1 Reply Last reply
                    0
                    • G Offline
                      G Offline
                      gentogen
                      wrote on sidst redigeret af
                      #654

                      Regarding the new Amivantamab: Eligible tumor types include non-small cell lung cancer (NSCLC), squamous cell carcinoma of the head and neck (SCCHN), hepatocellular cancer (HCC), colorectal cancer (CRC), renal cell cancer (RCC), medullary thyroid cancer (MTC), gastroesophageal cancer (GEC), mesothelioma, breast cancer (BC) and ovarian cancer (OC).

                      1 Reply Last reply
                      0
                      • P Offline
                        P Offline
                        peter12
                        wrote on sidst redigeret af
                        #655

                        Det lyder forkert. Hvor står det ?

                        1 Reply Last reply
                        0
                        • P Offline
                          P Offline
                          peter12
                          wrote on sidst redigeret af
                          #656

                          Ok tak, jeg var ikke klar over at alle de tumor typer udtrykte EGFR og cMet. Interessant 😉

                          1 Reply Last reply
                          0
                          • G Offline
                            G Offline
                            gentogen
                            wrote on sidst redigeret af
                            #657

                            High expression of c-Met and EGFR is associated with poor survival of patients with glottic laryngeal squamous cell carcinoma

                            1 Reply Last reply
                            0
                            • G Offline
                              G Offline
                              gentogen
                              wrote on sidst redigeret af
                              #658

                              https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5769407/

                              1 Reply Last reply
                              0
                              • G Offline
                                G Offline
                                GeorgeBest
                                wrote on sidst redigeret af
                                #659

                                Amivantamab har potentiale til at blive stort...

                                1 Reply Last reply
                                0
                                • Helge_LarsenPI-redaktørH Offline
                                  Helge_LarsenPI-redaktørH Offline
                                  Helge_LarsenPI-redaktør
                                  wrote on sidst redigeret af
                                  #660

                                  God morgen. 🙂

                                  1 Reply Last reply
                                  0
                                  • Helge_LarsenPI-redaktørH Offline
                                    Helge_LarsenPI-redaktørH Offline
                                    Helge_LarsenPI-redaktør
                                    wrote on sidst redigeret af
                                    #661

                                    Q&A d. 27. nov. kl. 16.

                                    1 Reply Last reply
                                    0
                                    • Helge_LarsenPI-redaktørH Offline
                                      Helge_LarsenPI-redaktørH Offline
                                      Helge_LarsenPI-redaktør
                                      wrote on sidst redigeret af
                                      #662

                                      Aktier/tendens: Vestas og DSV i fokus i nervøst marked: https://www.proinvestor.com/investornyt/669096/aktier-tendens-vestas-og-dsv-i-fokus-i-nervost-marked

                                      1 Reply Last reply
                                      0
                                      • E Offline
                                        E Offline
                                        E_L
                                        wrote on sidst redigeret af
                                        #663

                                        Daratumumab efficacy in extramedullary orbital myeloma https://onlinelibrary.wiley.com/doi/full/10.1002/ccr3.3458

                                        1 Reply Last reply
                                        0
                                        • E Offline
                                          E Offline
                                          E_L
                                          wrote on sidst redigeret af
                                          #664

                                          AMGEN: KYPROLIS® (carfilzomib) sales decreased 2% year-over-year driven by volume declines, as fewer new patients began treatment due to COVID-19. Early indications point to a strong launch of the new once-weekly KYPROLIS and DARZALEX® (daratumumab) combination regimen that was approved by the U.S. Food and Drug Administration (FDA) in August.

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind

                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          • First post
                                            Last post
                                          0
                                          • Debatforum
                                          • Seneste
                                          • Populære
                                          • Bruger